From GlobeNewswire:

The Biochips Market is estimated to reach USD 41.8 Billion by 2034, growing at a CAGR of 14.8% from USD 10.5 Billion in 2024. Biochips are miniaturized devices used for high-throughput analysis of biological interactions, gene expression, genotyping, and disease diagnostics. Key players include CDI labs, ThermoFisher, Illumina, and Agilent Technologies. The market is driven by advancements in biotechnology, precision medicine, and drug discovery, with opportunities in point-of-care testing, liquid biopsy, single-cell analysis, and AI-driven analytics. Challenges include data privacy, competition, and market saturation. Major regional markets include North America, Europe, Asia Pacific, and Latin America, with North America leading in clinical diagnostics and personalized medicine applications. The market is segmented by product (DNA chip, protein chip, lab-on-a-chip), application (drug discovery, diagnostics, genomics, proteomics), and end-user (biotech, hospitals, research institutes). Opportunities for growth lie in agricultural, environmental, and food safety testing applications, as well as the integration of microfluidic and AI technologies in biochip platforms.



Read more at GlobeNewswire: Biochips Market to Exceed USD 41.8 Billion by 2034, with a